Compare Anheuser-Busch Inbev SA (BUD) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Anheuser-Busch Inbev SA vs Merck & Co., Inc. — how do they compare? Anheuser-Busch Inbev SA trades at $79.78 (market cap $153.45B), while Merck & Co., Inc. trades at $123.7 (market cap $298.31B). The key difference: Merck & Co., Inc. is the larger of the two by market cap, and Merck & Co., Inc. pays the higher dividend (2.82%). Which is the better fit depends on your goals.
| BUD | MRK | |
|---|---|---|
Market Cap | $153.45B | $298.31B |
Sector | Consumer Staples | Health |
52-Week High | $85.09 | $129.52 |
52-Week Low | $57.10 | $77.60 |
Enterprise Value | $214.64B | $341.72B |
Dividend Yield | 1.7% | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BUD trades at $79.33, down 0.35% with bearish technical signals. The company demonstrates solid fundamentals with consistent earnings beats, 11.9% net margin, and improving cash flow. Recent dividend payment of $1.17 and positive analyst sentiment with 57.8% buy ratings support the investment case. Premiumization strategy and digital expansion drive growth amid changing consumer preferences.
Outlook remains positive with $90.08 consensus price target offering 13.5% upside. Key risks include alcohol moderation trends and competitive pressures. Strong balance sheet with declining debt-to-asset ratio to 33.9% provides financial stability. Revenue growth expected to accelerate to $61B in 2026 with expanding margins.
Merck (MRK) trades at $123.52, down 0.41% on the day, amid a bullish technical signal and strong institutional interest. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives. Valuation ratios include a P/E of 34.02 and P/S of 4.58, while cash flow from operations remains healthy at $16.47B in 2025.
The outlook for MRK is positive, driven by earnings beats, a dominant oncology portfolio, and analyst consensus favoring buys. Key risks include rising debt levels, with debt-to-asset ratio increasing to 36.06 in 2025, and competitive pressures in the pharmaceutical sector. The stock offers potential upside to the consensus price target of $137.30, but investors should monitor execution risks from recent acquisitions and macroeconomic factors affecting healthcare spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
